Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.36 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | CDK9 | P50750 | 4/20 | 0.36 |
| ▸ | CCNK | O75909 | 3/20 | 0.36 |
| ▸ | CDK13 | Q14004 | 3/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | PDE8B | O95263 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119871 | 0.95 | PDE10A (0.52) | PDE10AESR1CCNT1CCNE1CDK2 | |
| SCHEMBL20119754 | 0.84 | KCNH3 (0.34) | PDE10AESR1CCNT1CCNE1CDK2 | |
| SCHEMBL20119863 | 0.81 | PDE10A (0.40) | PDE10AESR1CCNT1CCNE1CDK2 | |
| SCHEMBL20119762 | 0.80 | PDE10A (0.36) | PDE10ACCNE1CDK2ADORA3IGF1R | |
| SCHEMBL20119458 | 0.79 | KDM4C (0.39) | PDE10ACCNE1CDK2KDRPDE5A | |
| SCHEMBL20119678 | 0.79 | HRH4 (0.37) | PDE10AESR1ADORA3IGF1R | |
| SCHEMBL20119658 | 0.79 | SMN1; SMN2 (0.48) | ADORA3ADORA1 | |
| SCHEMBL20119508 | 0.77 | KDM4C (0.41) | PDE10AESR1CCNE1CDK2KDR | |
| SCHEMBL20119605 | 0.76 | YTHDC1 (0.43) | PDE10ACCNE1CDK2KDRPDE5A | |
| SCHEMBL20119907 | 0.75 | CCNE2 (0.44) | PDE10ACCNE1CDK2KDRPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | PDE10A 2441/4885ESR1 4474/4885CCNT1 4469/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | PDE10A 2441/4885ESR1 4474/4885CCNT1 4469/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | PDE10A 2441/4885ESR1 4474/4885CCNT1 4469/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | PDE10A 2441/4885ESR1 4474/4885CCNT1 4469/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | PDE10A 2441/4885ESR1 4474/4885CCNT1 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.